New discoveries for an old drug: a review of recent olanzapine research

References

• Martin WF, Correll CU, Weiden PJ, et al. Mitigation of Olanzapine-induced weight gain with samidorphan, an opioid antagonist: A RANDOMIZED double-blind phase 2 study in patients with Schizophrenia. Am J Psychiatry. 2019 Jun 1;176(6):457–467.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019 Feb;18(1):53–66.
   PubMed Web of Science ®Google Scholar
• Citrome L, Kantrowitz JT. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Expert Rev Neurother. 2009 Jul;9(7):1045–1058.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf. 2008 Nov;7(6):761–769.
   PubMed Web of Science ®Google Scholar
• Hermann RC, Yang D, Ettner SL, et al. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv. 2002 Apr;53(4):425–430.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan J, Puumala SE. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors. Clin Ther. 2007 Apr;29(4):723–741.
   PubMed Web of Science ®Google Scholar
• Weinbrenner S, Assion HJ, Stargardt T, et al. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund. Pharmacopsychiatry. 2009 Mar;42(2):66–71.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010 Jan;36(1):71–93.
   PubMed Web of Science ®Google Scholar
• Halfdanarson O, Zoega H, Aagaard L, et al. International trends in antipsychotic use: A study in 16 countries, 2005-2014. Eur Neuropsychopharmacol. 2017 Oct;27(10):1064–1076.
   PubMed Web of Science ®Google Scholar
• Hojlund M, Munk-Jorgensen P. Differences in antipsychotic prescriptions between centers in young outpatients with Schizophrenia. J Clin Psychopharmacol. 2017 Dec;37(6):753–754.
   PubMed Web of Science ®Google Scholar
• Yazici E, SC A, Yazici AB, et al. Antipsychotic use pattern in schizophrenia outpatients: correlates of polypharmacy. Clin Pract Epidemiol Ment Health. 2017;13:92–103.
   PubMedGoogle Scholar
• Joshi K, Lin J, Lingohr-Smith M, et al. Treatment patterns and antipsychotic medication adherence among commercially insured patients with Schizoaffective disorder in the United States. J Clin Psychopharmacol. 2016 Oct;36(5):429–435.
   PubMed Web of Science ®Google Scholar
• Hollingworth SA, Siskind DJ, Nissen LM, et al. Patterns of antipsychotic medication use in Australia 2002-2007. Aust N Z J Psychiatry. 2010 Apr;44(4):372–377.
   PubMed Web of Science ®Google Scholar
• Seshadri M, Elsemary A, Thalitaya MD, et al. Study on the prescribing patterns of antipsychotic medication in a rural England community mental health team. Psychiatr Danub. 2017 Sep;29(Suppl 3):524–529.
   PubMedGoogle Scholar
• Robinson DG, Schooler NR, John M, et al. Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry. 2015 Mar 1;172(3):237–248.
   PubMed Web of Science ®Google Scholar
• Roh D, Chang JG, Yoon S, et al. Antipsychotic prescribing patterns in first-episode Schizophrenia: a five-year comparison. Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):275–282.
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019 Jul 11;394(10202):939–951.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Soares-Weiser K, Bechard-Evans L, Lawson AH, et al. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2013 Feb;23(2):118–125.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Nitta M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019 Jun;18(2):208–224.
   PubMed Web of Science ®Google Scholar
• Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant Schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016 Mar;73(3):199–210.
   PubMed Web of Science ®Google Scholar
• Souza JS, Kayo M, Tassell I, et al. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr. 2013 Apr;18(2):82–89.
   PubMed Web of Science ®Google Scholar
• Zhang JP, Gallego JA, Robinson DG, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013 Jul;16(6):1205–1218.
   PubMed Web of Science ®Google Scholar
• Krause M, Zhu Y, Huhn M, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol. 2018 Jun;28(6):659–674.
   PubMed Web of Science ®Google Scholar
• Devoe DJ, Farris MS, Townes P, et al. Attenuated psychotic symptom interventions in youth at risk of psychosis: A systematic review and meta-analysis. Early Interv Psychiatry. 2019 Feb;13(1):3–17.
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bighelli I, So R, et al. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res. 2017;183:10–21.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT. Managing negative symptoms of Schizophrenia: how far have we come? CNS Drugs. 2017 May;31(5):373–388.
   PubMed Web of Science ®Google Scholar
• Ayesa-Arriola R, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. Psychopharmacology (Berl). 2013 Jun;227(4):615–625.
   PubMed Web of Science ®Google Scholar
• Nielsen RE, Levander S, Kjaersdam Telleus G, et al. Second-generation antipsychotic effect on cognition in patients with schizophrenia–a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015 Mar;131(3):185–196.
   PubMed Web of Science ®Google Scholar
• Novick D, Montgomery W, Treuer T, et al. Real-world effectiveness of antipsychotics for the treatment of negative symptoms in patients with Schizophrenia with predominantly negative symptoms. Pharmacopsychiatry. 2017 Mar;50(2):56–63.
   PubMed Web of Science ®Google Scholar
• Luan S, Wan H, Wang S, et al. Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2017;13:609–620.
   PubMed Web of Science ®Google Scholar
• Samara MT, Goldberg Y, Levine SZ, et al. Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. Lancet Psychiatry. 2017 Nov;4(11):859–867.
   PubMed Web of Science ®Google Scholar
• Hunt GE, Large MM, Cleary M, et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis. Drug Alcohol Depend. 2018 Oct 1;191:234–258.
   PubMed Web of Science ®Google Scholar
• Krause M, Huhn M, Schneider-Thoma J, et al. Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2019 Jan;29(1):32–45.
   PubMed Web of Science ®Google Scholar
• Dundar Y, Greenhalgh J, Richardson M, et al. Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis. Hum Psychopharmacol. 2016 Jul;31(4):268–285.
   PubMed Web of Science ®Google Scholar
• Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007 Dec;68(12):1876–1885.
   PubMed Web of Science ®Google Scholar
• Tan L, Tan L, Wang HF, et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimer’s Res Ther. 2015;7(1):20.
   PubMed Web of Science ®Google Scholar
• Dold M, Aigner M, Klabunde M, et al. Second-generation antipsychotic drugs in anorexia nervosa: a meta-analysis of randomized controlled trials. Psychother Psychosom. 2015;84(2):110–116.
   PubMed Web of Science ®Google Scholar
• Attia E, Steinglass JE, Walsh BT, et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. Am J Psychiatry. 2019 Jun 1;176(6):449–456.
   PubMed Web of Science ®Google Scholar
• Chiu L, Chow R, Popovic M, et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer. 2016 May;24(5):2381–2392.
   PubMed Web of Science ®Google Scholar
• Yang T, Liu Q, Lu M, et al. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul;83(7):1369–1379.
   PubMed Web of Science ®Google Scholar
• Yoodee J, Permsuwan U, Nimworapan M. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Apr;112:113–125.
   PubMed Web of Science ®Google Scholar
• Sutherland A, Naessens K, Plugge E, et al. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018 Sep;21(9):CD012555.
   Google Scholar
• Herrstedt J, Summers Y, Jordan K, et al. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. Support Care Cancer. 2019 Jul;27(7):2699–2705.
   PubMed Web of Science ®Google Scholar
• Spertus J, Horvitz-Lennon M, Abing H, et al. Risk of weight gain for specific antipsychotic drugs: a meta-analysis. NPJ Schizophr. 2018 Jun 27;4(1):12.
   PubMed Web of Science ®Google Scholar
• Musil R, Obermeier M, Russ P, et al. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015 Jan;14(1):73–96.
   PubMed Web of Science ®Google Scholar
• Lin CH, Lin SC, Huang YH, et al. Early prediction of olanzapine-induced weight gain for schizophrenia patients. Psychiatry Res. 2018;263:207–211.
   PubMed Web of Science ®Google Scholar
• Buhagiar K, Jabbar F. Association of first- vs. second-generation antipsychotics with lipid abnormalities in individuals with severe mental illness: a systematic review and meta-analysis. Clin Drug Investig. 2019 Mar;39(3):253–273.
   PubMed Web of Science ®Google Scholar
• Pillinger T, Beck K, Gobjila C, et al. Impaired glucose homeostasis in first-episode Schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 2017 Mar 1;74(3):261–269.
   PubMed Web of Science ®Google Scholar
• Rajkumar AP, Horsdal HT, Wimberley T, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with Schizophrenia: a danish population-based cohort study. Am J Psychiatry. 2017 Jul 1;174(7):686–694.
   PubMed Web of Science ®Google Scholar
• Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019 Sep 2;19(10):96.
   PubMed Web of Science ®Google Scholar
• Hardy TA, Henry RR, Forrester TD, et al. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes Obes Metab. 2011 Aug;13(8):726–735.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Y, Su Y, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017 Nov 21;17(1):373.
   PubMed Web of Science ®Google Scholar
• Samalin L, Garay R, Ameg A, et al. Olanzapine pamoate for the treatment of schizophrenia–a safety evaluation. Expert Opin Drug Saf. 2016;15(3):403–411.
   PubMed Web of Science ®Google Scholar
• Tek C, Kucukgoncu S, Guloksuz S, et al. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2016 Jun;10(3):193–202.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008 Aug;28(4):392–400.
   PubMed Web of Science ®Google Scholar
• Citrome L, Stauffer VL, Chen L, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol. 2009 Jun;29(3):278–283.
   PubMed Web of Science ®Google Scholar
• Adesola A, Anozie I, Erohubie P, et al. Prevalence and correlates of “high dose” antipsychotic prescribing: findings from a hospital audit. Ann Med Health Sci Res. 2013 Jan;3(1):62–66.
   PubMedGoogle Scholar
• Roh D, Chang JG, Kim CH, et al. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust N Z J Psychiatry. 2014 Jan;48(1):52–60.
   PubMed Web of Science ®Google Scholar
• Morrissette DA, Stahl SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. 2014 Oct;19(5):439–448.
   PubMed Web of Science ®Google Scholar
• Westermeyer J. Call for “High-Dose” Olanzapine research in treatment-resistant psychosis. J Nerv Ment Dis. 2019 Jan;207(1):45–47.
   PubMed Web of Science ®Google Scholar
• Edlinger M, Rettenbacher MA, Kemmler G, et al. Prescribing practice in inpatients versus outpatients with Schizophrenia initiating treatment with second-generation antipsychotics: a naturalistic follow-up study. J Clin Psychopharmacol. 2016 Dec;36(6):621–627.
   PubMed Web of Science ®Google Scholar
• Perera V, Forrest A, Xu J. High-dose olanzapine for bipolar depression: proceed with caution. Prim Care Companion CNS Disord. 2014;16:5.
   Google Scholar
• Batail JM, Langree B, Robert G, et al. Use of very-high-dose olanzapine in treatment-resistant schizophrenia. Schizophr Res. 2014 Nov;159(2–3):411–414.
   PubMed Web of Science ®Google Scholar
• Hatta K, Takebayashi H, Sudo Y, et al. The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia. Psychiatry Res. 2013 Dec 15;210(2):396–401.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Richardson CM, Yu Y, et al. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol. 2006 Aug;21(6):393–398.
   PubMed Web of Science ®Google Scholar
• Agid O, Schulze L, Arenovich T, et al. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol. 2013 Sep;23(9):1017–1022.
   PubMed Web of Science ®Google Scholar
• Kishi T, Suzuki T, Sekiguchi H, et al. Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia. Asian J Psychiatr. 2013 Feb;6(1):86–87.
   PubMedGoogle Scholar
• Sakurai H, Suzuki T, Bies RR, et al. Increasing versus maintaining the dose of Olanzapine or risperidone in schizophrenia patients who did not respond to a modest dosage: a double-blind randomized controlled trial. J Clin Psychiatry. 2016 Oct;77(10):1381–1390.
   PubMed Web of Science ®Google Scholar
• Ermilov M, Gelfin E, Levin R, et al. A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Schizophr Res. 2013 Nov;150(2–3):604–605.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT. N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia. Schizophr Res. 2019 May;207:70–79.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Epstein ML, Lee M, et al. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: correlation with symptoms. Schizophr Res. 2018;191:70–79.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Woods SW, Petkova E, et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry. 2015 May;2(5):403–412.
   PubMed Web of Science ®Google Scholar
• Luckhoff H, Phahladira L, Scheffler F, et al. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12months. Schizophr Res. 2019;206:171–176.
   PubMed Web of Science ®Google Scholar
• Raben AT, Marshe VS, Chintoh A, et al. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment. Front Neurosci. 2017;11:741.
   PubMed Web of Science ®Google Scholar
• Zhuo C, Xu Y, Liu S, et al. Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis. Front Pharmacol. 2018;9:1393.
   PubMed Web of Science ®Google Scholar
• Choi YJ. Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. ScientificWorldJournal. 2015;2015:970730.
   PubMedGoogle Scholar
• Praharaj SK, Jana AK, Goyal N, et al. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011 Mar;71(3):377–382.
   PubMed Web of Science ®Google Scholar
• Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012 Sep;140(1–3):159–168.
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (New York, NY). 2005 Dec 9;310(5754):1642–1646.
   Google Scholar
• Ellul P, Delorme R, Cortese S. Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: a systematic review and meta-analysis. CNS Drugs. 2018 Dec;32(12):1103–1112.
   PubMed Web of Science ®Google Scholar
• Siskind D, Hahn M, Correll CU, et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019 Feb;21(2):293–302.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Citrome L. Lurasidone for schizophrenia: what’s different? Expert Rev Neurother. 2012 Mar;12(3):265–273.
   PubMed Web of Science ®Google Scholar
• Lin CH, Wang FC, Lin SC, et al. A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia. Schizophr Res. 2017;185:80–87.
   PubMed Web of Science ®Google Scholar
• Gu XJ, Chen R, Sun CH, et al. Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials. J Int Med Res. 2018 Jan;46(1):22–32.
   PubMed Web of Science ®Google Scholar
• Smith RC, Maayan L, Wu R, et al. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2018 Dec;235(12):3545–3558.
   PubMed Web of Science ®Google Scholar
• Barak N, Beck Y, Albeck JH, et al. Double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain. J Clin Psychopharmacol. 2016 Jun;36(3):253–256.
   PubMed Web of Science ®Google Scholar
• Modabbernia A, Heidari P, Soleimani R, et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res. 2014;53:133–140.
   PubMed Web of Science ®Google Scholar
• Ball MP, Warren KR, Feldman S, et al. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011 Apr;5(1):17–25.
   PubMedGoogle Scholar
• McElroy SL, Winstanley E, Mori N, et al. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol. 2012 Apr;32(2):165–172.
   PubMed Web of Science ®Google Scholar
• Taveira TH, Wu WC, Tschibelu E, et al. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study. J Psychopharmacol. 2014 Apr;28(4):395–400.
   PubMed Web of Science ®Google Scholar
• Correll C, Kahn R, Silverman B, et al., editors. A combination of olanzapine and samidorphan mitigates weight gain observed with olanzapine: results from the phase 3 ENLIGHTEN-2 schizophrenia study. 175th Annual Meeting of the American Psychiatric Association; May 18-22, 2019; San Francisco, California.
   Google Scholar